Previous 10 | Next 10 |
2024-01-23 03:22:09 ET Summary Briumvi shows increasing revenues but faces decelerating growth, suggesting possible market saturation or increased competition. TG Therapeutics has a strong balance sheet but contends with high SG&A costs, typical in early-stage commercializatio...
2024-01-10 10:00:05 ET Summary TG Therapeutics CEO Mike Weiss recently presented at the J.P. Morgan Healthcare Conference, sharing positive updates on Briumvi's Q4 2023 net sales and revenue guidance for 2024. 2024 revenue guidance and the expense guidance suggest the company shou...
2024-01-10 09:28:08 ET Shares of TG Therapeutics Inc (NASDAQ: TGTX) opened 11% up on Wednesday after the biopharmaceutical firm said it sees a meaningful increase in its revenue from Briumvi this year. TG Therapeutics issues outlook for 2024 The Nasdaq-listed firm is expected to...
2024-01-10 07:49:34 ET More on TG Therapeutics TG Therapeutics: The Revenue Beat Isn't What It Looks Like TG Therapeutics: Trying To Fill The Gap Back To $20 Precision BioSciences stock rises on $17.5M license deal with TG Therapeutic TG Therapeutics spikes; ...
Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively Preliminary year-end 2023 cash position of approximately $215 million NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NAS...
2024-01-09 09:42:05 ET A North Carolina-based biotech firm is turning heads so far Tuesday morning after it was announced a strategic transaction with TG Therapeutics Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and ot...
2024-01-09 07:55:05 ET Precision BioSciences ( NASDAQ: DTIL ) shares rallied 20% premarket on Tuesday after it entered into a $17.5M global licensing deal with with TG Therapeutic ( NASDAQ: TGTX ). Under the deal, TG Therapeutics ( TGTX ) will acquire a world...
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), “the Company,” today announced that it has entered into an agreement with Precision BioSciences , Inc. ( NASDAQ GS: DTIL) to acquire a worldwide license to Precision’s Azercabta...
2024-01-05 11:55:52 ET More on TG Therapeutics TG Therapeutics: The Revenue Beat Isn't What It Looks Like TG Therapeutics: Trying To Fill The Gap Back To $20 TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript TG Therapeutics spikes as Merck KGaA fl...
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place o...
News, Short Squeeze, Breakout and More Instantly...
2024-05-14 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) fell sharply during Wednesday's session as the company reported first-quarter results and ...
U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday. Shares of Powell Industries, Inc. (NASDAQ:POWL) rose sharply ...